Safety Study Evaluating the Adrenal Suppression Potential of Product 0405 in Pediatric Subjects With Atopic Dermatitis

• Status: Completed
• Trial end date: 2011-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the trial is to assess Adrenal Suppression potential when pediatric subjects are administered Product 0405 for the treatment of Atopic Dermatitis

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fougera Pharmaceuticals Inc.

Criteria

Inclusion Criteria:

• Clinical diagnosis of Atopic Dermatitis

• Good health with the exception of Atopic Dermatitis

• Percent body surface area minimum requirements

Exclusion Criteria:

• Subjects who are pregnant, nursing, or planning a pregnancy